Sign in
CompletedPhase 2

Bacteriophage Therapy TP-102 in Patients With Diabetic Foot Infection

Key facts

Who runs it
Technophage, SA
Where
Los Angeles and Webster, United StatesSee the 2 sitesAlso in 2 other countries, 13 sites
Status
Completed
Phase
Phase 2
People taking part
76 people enrolled
Started
8 Nov 2023
Ended
19 Dec 2025
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • TP-102
  • Placebo
Record updated
22 December 2025

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 22 criteriaShow less

Who can take part

  • Aged ≥18 years old
  • Established diagnosis of Diabetes Mellitus (type I or II)
  • Glycosylated hemoglobin (HbA1c) value < 12.0%
  • Designated foot infection meets the following criteria:
  • Present for at least 3 weeks
  • Below-ankle, full-thickness, cutaneous ulcer
  • Wound area (after debridement, if applicable) 1 to 20.0 cm2
  • PEDIS infection grade 2 or 3
  • PEDIS perfusion grade 1 or 2
  • PEDIS depth grade 1 or 2 (grade 3 at the discretion of the investigator e.g. if they have received appropriate surgical treatment to remove infected bones)
  • Diabetic foot infection with at least one target bacterial strain (Pseudomonas aeruginosa, Staphylococcus aureus or Acinetobacter baumannii), susceptible to the TP-102 bacteriophage cocktail, as assessed from wound cultures
  • Patients of suitable physical and mental health as determined by the Investigator on the basis of medical history and general physical examination
  • Patients of childbearing potential must have a negative serum pregnancy test at screening
  • ICF signed voluntarily before any study-related procedure is performed, indicating that the patient understands the purpose of, and procedures required in the study and is willing to participate in the study

Who cannot take part

  • Patient receiving hyperbaric oxygen therapy (HBOT), negative pressure wound therapy (NPWT), bioengineering skin (BES) substitutes and/or growth factors
  • Currently participating in another clinical trial or having participated in a previous clinical trial with receipt of an investigational product within 30 days of the first administration of IP
  • Participants with hypersensitivity to any component of investigational products
  • Infected study ulcer less than 2 cm away from other ulcers, in the case of multiple ulcers
  • Presence of active malignant or benign tumors of any kind, (with exception to nonmelanoma skin cancer as per investigator's discretion)
  • A condition that, in the opinion of the Investigator, could compromise the well-being of the patient or course of the study, or prevent the patient from meeting or performing any study requirements
  • Patient which, in the opinion of the investigator, may not comply with study related procedures
  • Being pregnant or breastfeeding

Where in United States

Also in 2 other countries, 13 sites

  • Clemente Clinical ResearchLos Angeles, United States
  • Tranquil Clinical ResearchWebster, United States

About the trial

What the trial wants to find out

TP-102 is a novel bacteriophage cocktail comprised of 5 (five) lytic bacteriophages against Staphylococcus aureus, Pseudomonas aeruginosa, and Acinetobacter baumannii. TP-102 is being developed for topical treatment of patients with wound infections including chronic ulcers; applied every other day (three times weekly (TIW)).

The 2 groups in the trial

  • TP-102Treatment being tested

    Patients will be randomly assigned in a 1:1 ratio to one of two treatment arms at Day 1. The wound standard of care (SoC) procedures shall be in accordance to each sites normal DFI routine.

  • PlaceboPlacebo, for comparison

    Patients will be randomly assigned in a 1:1 ratio to one of two treatment arms at Day 1. The wound standard of care (SoC) procedures shall be in accordance to each sites normal DFI routine.

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
A Phase 2 CT to Evaluate the Safety and Efficacy of Topical Administration of Bacteriophage Therapy TP-102 in Patients With DFI
Record updated
22 December 2025